Table 2 Comparative efficacy and safety between infliximab and vedolizumab in patients with ulcerative colitis
Outcome | Treatment | Participants, N | Infliximab and biosimilars, estimate (95% CI)a | Heterogeneity (%) |
|---|---|---|---|---|
Efficacy: Induction phase (Week 6) | ||||
Clinical responseb | Infliximab | 242 | 67% (61%, 73%) | 0 |
Vedolizumab | 608 | 52% (46%, 58%) | 78 | |
Mucosal healing | Infliximab | 242 | 61% (55%, 67%) | 0 |
Clinical remissionb | Infliximab | 242 | 36% (31%, 43%) | 0 |
Vedolizumab | 608 | 21% (16%, 28%) | 82 | |
Efficacy: Maintenance phase (Week 50 to 54) | ||||
Clinical responseb | Infliximab | 198 | 54% (43%, 65%) | 62 |
Vedolizumab | 282 | 63% (56%, 69%) | 51 | |
Mucosal healing | Infliximab | 198 | 49% (43%, 56%) | 2 |
Vedolizumab | 665 | 49% (42%, 57%) | 78 | |
Clinical remissionb | Infliximab | 198 | 43% (33%, 54%) | 60 |
Vedolizumab | 665 | 39% (33%, 46%) | 73 | |
Safety (≤ 1 year) | ||||
Any AE | Infliximab | 214 | 75% (60%, 86%) | 86 |
Vedolizumab | 543 | 64% (60%, 68%) | 44 | |
Any SAE | Infliximab | 214 | 12% (6%, 23%) | 72 |
Vedolizumab | 543 | 11% (9%, 14%) | 0 | |
Any infection | Infliximab | 214 | 21% (8%, 43%) | 91 |
Vedolizumab | 543 | 26% (22%, 29%) | 14 | |
Any serious infection | Infliximab | 242 | 2% (1%, 5%) | 0 |
Vedolizumab | 489 | 2% (1%, 3%) | 0 | |
Discontinuation due to AE | Infliximab | 214 | 4% (1%, 14%) | 0 |
Vedolizumab | 667 | 5% (3%, 7%) | 0 | |
Discontinuation due to lack of efficacy | Vedolizumab | 667 | 15% (10%, 22%) | 82 |